PRZOOM - /newswire/ -
Mountain View, CA, United States, 2015/05/07 - Long term clinical trials will increase likelihood of prescriptions receiving approval and adoption by physicians, finds Frost & Sullivan - LifeSciences.Frost.com.
The innovation of therapeutic platforms have driven the multiple sclerosis (MS) therapeutics market to enter a new phase of growth in the U.S. Oral therapies are revolutionizing the treatment paradigm of MS, offering enhanced dosing and patient compliance.
Analysis from Frost & Sullivan, A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market, finds that recent therapeutic advancements aim at improving the tolerability of existing products, specifically for interferon beta and glatiramer acetate. Developing anti-inflammatory medications has also been a key area of focus.
“Physicians prefer Avonex, Betaferon, Copaxone, Rebif or ABCRs as first line therapy because of the 10 years of clinical data establishing their efficacy and safety,” said Frost & Sullivan Healthcare Industry Analyst Aish Vivekanandan. “As is evident, clinical data substantiating the benefits of drugs will prove to be the driving factor in enabling rapid approvals from regulatory agencies.”
Relapsing-remitting multiple sclerosis (RRMS) is the most common form of MS particularly in the U.S. and Europe, and garners immense attention from drug manufacturers. Although, therapeutic drug development in the primary progressive multiple sclerosis (PPMS) segment leaves a lot to be desired.
Drug manufacturers are now investing in R&D to achieve a greater understanding of PPMS disease pathology and reach this untapped market. Clinical studies researching the treatment of progressive MS and investigating the effects of vitamin D in relapsing MS are also underway.
“Many pharmaceutical companies are gradually realizing the importance of long-term clinical studies for drugs,” noted Vivekanandan. “This awareness could spur pharmaceuticals to develop low-risk drugs for the treatment of MS and build a patient base in a market with huge unmet medical needs.”
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market is a Market Insight that is part of the Life Sciences (lifesciences.frost.com) Growth Partnership Service program. The analysis looks at MS pharmaceutical drugs currently in the market, as well as, drugs in the third phase of trials and poses a potential threat to competitors. The study offers a competitive evaluation of these drugs and the predicted outcome and impact of each of them.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on “the next big thing" | Register: Gain access to visionary innovation
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market / NEC3-52